Jacobs Levy Equity Management Inc. Takes $1.03 Million Position in Omeros Co. (NASDAQ:OMER)

Jacobs Levy Equity Management Inc. bought a new position in shares of Omeros Co. (NASDAQ:OMER - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 104,538 shares of the biopharmaceutical company's stock, valued at approximately $1,033,000. Jacobs Levy Equity Management Inc. owned about 0.18% of Omeros as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Truvestments Capital LLC raised its stake in Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 1,972 shares during the last quarter. Quantbot Technologies LP bought a new position in Omeros during the fourth quarter worth $46,000. Picton Mahoney Asset Management raised its stake in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after buying an additional 4,404 shares during the last quarter. Finally, US Bancorp DE bought a new position in Omeros during the fourth quarter worth $81,000. Institutional investors own 48.79% of the company's stock.

Wall Street Analysts Forecast Growth

OMER has been the subject of a number of analyst reports. D. Boral Capital reissued a "buy" rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, May 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research note on Friday, May 16th. Finally, Wall Street Zen raised shares of Omeros from a "sell" rating to a "hold" rating in a research note on Monday. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Omeros currently has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Stock Down 0.2%

OMER traded down $0.01 during midday trading on Thursday, hitting $3.11. The company had a trading volume of 299,822 shares, compared to its average volume of 660,319. Omeros Co. has a 52 week low of $2.97 and a 52 week high of $13.60. The company has a market capitalization of $181.04 million, a price-to-earnings ratio of -1.35 and a beta of 2.42. The stock's 50 day moving average price is $6.77 and its 200 day moving average price is $8.09.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.05). Research analysts predict that Omeros Co. will post -3.09 EPS for the current year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.